202 related articles for article (PubMed ID: 24074814)
21. Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
Bazan JG; Luxton G; Kozak MM; Anderson EM; Hancock SL; Kapp DS; Kidd EA; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):983-91. PubMed ID: 24161422
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Toxicity Between Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy for Locally Advanced Non-small-cell Lung Cancer.
Ling DC; Hess CB; Chen AM; Daly ME
Clin Lung Cancer; 2016 Jan; 17(1):18-23. PubMed ID: 26303127
[TBL] [Abstract][Full Text] [Related]
23. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced non-small cell lung cancer.
Li BS; Gong HY; Huang W; Yi Y; Yu JM; Wang ZT; Zhang ZC; Sun HF; Li HS; Wang LY
Am J Clin Oncol; 2012 Apr; 35(2):115-9. PubMed ID: 21555933
[TBL] [Abstract][Full Text] [Related]
25. Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal.
Bazan JG; Luxton G; Mok EC; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):700-6. PubMed ID: 22414279
[TBL] [Abstract][Full Text] [Related]
26. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
[TBL] [Abstract][Full Text] [Related]
27. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
[TBL] [Abstract][Full Text] [Related]
28. Incidence and Predictors of Pericardial Effusion After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.
Ning MS; Tang L; Gomez DR; Xu T; Luo Y; Huo J; Mouhayar E; Liao Z
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):70-79. PubMed ID: 28816165
[TBL] [Abstract][Full Text] [Related]
29. Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer.
Rosenzweig KE; Mychalczak B; Fuks Z; Hanley J; Burman C; Ling CC; Armstrong J; Ginsberg R; Kris MG; Raben A; Leibel S
Cancer J; 2000; 6(2):82-7. PubMed ID: 11069224
[TBL] [Abstract][Full Text] [Related]
30. Dosimetric parameters predictive of acute gastrointestinal toxicity in patients with anal carcinoma treated with concurrent chemotherapy and intensity-modulated radiation therapy.
DeFoe SG; Kabolizadeh P; Heron DE; Beriwal S
Oncology; 2013; 85(1):1-7. PubMed ID: 23736101
[TBL] [Abstract][Full Text] [Related]
31. Three-times-daily radiotherapy with induction chemotherapy in locally advanced non-small cell lung cancer. Feasibility and toxicity study.
Catalano G; Jereczek-Fossa BA; De Pas T; Leon ME; Cattani F; Spaggiari L; Veronesi G; de Braud F; Orecchia R
Strahlenther Onkol; 2005 Jun; 181(6):363-71. PubMed ID: 15925978
[TBL] [Abstract][Full Text] [Related]
32. Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.
Barney CL; Scoville N; Allan E; Ayan A; DiCostanzo D; Haglund KE; Grecula J; Williams T; Xu-Welliver M; Otterson GA; Bazan JG
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):748-755. PubMed ID: 29413286
[TBL] [Abstract][Full Text] [Related]
33. Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy.
Rodríguez N; Algara M; Foro P; Lacruz M; Reig A; Membrive I; Lozano J; López JL; Quera J; Fernández-Velilla E; Sanz X
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):810-7. PubMed ID: 18755556
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of pemetrexed and cisplatin with concurrent high-dose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced non-small cell lung cancer.
Mornex F; Peignaux K; Germain T; Wautot V; Chouaki N; Bourayou N; Tourani JM
Lung Cancer; 2013 Apr; 80(1):68-74. PubMed ID: 23332163
[TBL] [Abstract][Full Text] [Related]
35. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: A retrospective study.
Xu Y; Zheng X; Bai X; Li P; Ma H; Wang J; Hu X; Chen M
Oncotarget; 2017 Jul; 8(30):49084-49092. PubMed ID: 28467775
[TBL] [Abstract][Full Text] [Related]
36. Duodenal and other gastrointestinal toxicity in cervical and endometrial cancer treated with extended-field intensity modulated radiation therapy to paraaortic lymph nodes.
Poorvu PD; Sadow CA; Townamchai K; Damato AL; Viswanathan AN
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1262-8. PubMed ID: 23182395
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer.
Cardenal F; Arnaiz MD; Morán T; Jové J; Nadal E; Porta R; Solé JM; Brao I; Palmero R; Fuentes R; Núñez I; Caveda E; Cassinello A
Lung Cancer; 2011 Oct; 74(1):69-74. PubMed ID: 21353323
[TBL] [Abstract][Full Text] [Related]
38. Outcome and toxicity of intensity modulated radiotherapy with simultaneous integrated boost in locally advanced non-small cell lung cancer patients.
Fondevilla Soler A; López-Guerra JL; Dzugashvili M; Sempere Rincón P; Sautbaet A; Castañeda P; Díaz JM; Praena-Fernandez JM; Rivin Del Campo E; Azinovic I
Clin Transl Oncol; 2017 Dec; 19(12):1469-1477. PubMed ID: 28589434
[TBL] [Abstract][Full Text] [Related]
39. Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer.
Colaco RJ; Huh S; Nichols RC; Morris CG; D'Agostino H; Flampouri S; Li Z; Pham DC; Bajwa AA; Hoppe BS
Acta Oncol; 2013 Apr; 52(3):506-13. PubMed ID: 23438357
[TBL] [Abstract][Full Text] [Related]
40. Dose-escalated Hypofractionated Intensity-modulated Radiation Therapy With Concurrent Chemotherapy for Inoperable or Unresectable Non-Small Cell Lung Cancer.
Kim JO; Chu KP; Fairchild A; Ghosh S; Butts C; Chu Q; Gabos Z; Joy AA; Nijjar T; Robinson DM; Sangha R; Scrimger R; Smylie M; Yee D; Roa WH
Am J Clin Oncol; 2017 Jun; 40(3):294-299. PubMed ID: 25333733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
